12th Annual IBA World Life Sciences Conference

Subjects include:
 
- Clinical trials: current trends and perspectives at a global level
- Data exclusivity/Bolar - the EU Pharma Package and other jurisdictions
- Antitrust and intellectual property - divisionals, patent settlements, unlawful PTEs and PTAs
- Preventive health and longevity: legal perspectives shaping the future of healthcare
- Cross-border intellectual property litigation
- Integration of pharma and MedTech with hospitals, clinics and pharmacies
- Liability and accountability in open science research
- Combination products (drug-device) regulation: emerging legal complexities
- Preparing for the entry into force of the WIPO GRATK Treaty
- Artificial intelligence and biotechnology: rethinking patent standards
- AI and data rights in life sciences and HealthTech deals (training data, model outputs and infringement risk)
- Collaboration and licensing structures as financing tools
- Life sciences M and A in uncertain markets - earnouts, contingent value rights, contingent milestones and intellectual property-driven valuation mechanics
- Late-stage private financings and IPO alternatives (crossovers, structured preferred, PIPEs, ATMs, registered directs)
- Cross-border investment constraints affecting financings and exits (CFIUS risk, sensitive health/genomic data and closing conditions)